Real-time insights. Smarter decisions. Better trades.
🔍 Search StocksConfidence: 35%
Date: 20-04-2026
Price: $0.010
Last Price: $0.010
Post-Signal Peak Price: $0.011
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a study
MELBOURNE, Australia AND SAN FRANCISCO, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the Company’s Phase 2
Alterity Therapeutics was founded in Melbourne, Australia in 1997 under the name Prana Biotechnology. Focusing on treatments for neurodegenerative diseases, the firm hopes to disrupt current medical thought on these conditions, offering alternatives for patients with any prognosis. With offices in M
AI Confidence - 35 % model confidence
Alterity Therapeutics Limited is a clinical-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, primarily Parkinson's disease and Friedreich's ataxia. The company leverages proprietary drug candidates to address unmet medical needs in these niche markets, positioning itself as a specialized player in rare neurological disorders.
| Cash Flow | Weak |
| Debt | Moderate |
| Profitability | Weak |
| Revenue Trend | Unknown |
| Trend | Bullish |
| Momentum | Moderate |
| RSI Signal | Neutral |
| Support Level | $ 0.0080 |
| Resistance Level | $ 0.0120 |